NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...

The biotech will now take atebimetinib to mid- and late-stage trials in NSCLC and pancreatic cancer, respectively.

PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...

Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...

Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...